Portland, OR -- (SBWIRE) -- 07/17/2017 -- Oral Proteins and Peptides Market are the formulations that are orally administered by the patient. Usually, formulations containing proteins and peptides are administered via intravenous and subcutaneous route due to instability and sensitivity towards body fluids. Oral route of administration is very convenient route; however, the bioavailability of proteins and peptides is less, when administered orally due to degradation of amino acids in gastrointestinal tract. With the advancement in technology formulation containing protein and peptides are introduced in the market that can be orally administered with no change in therapeutic activity and pharmacokinetic aspects.

Early buyers will receive 20% customization on this report.

The market for oral protein and peptides is expected to grow due to technological advancements, R&D activities and increase in prevalence of chronic disorders. High cost of R&D activities is the major challenge for oral proteins and peptides market.

Oral Proteins and Peptides Market analysis by Drugs

The market is segmented into Linaclotide, Ostora, IN-105(Insulin), Plecantide and others. Insulin is used mostly amongst the various oral proteins and peptides that are being developed.

Get PDF of this Report @ https://www.alliedmarketresearch.com/request-toc-and-sample/378

Oral Proteins and Peptides Market analysis by Technology

The market is segmented into Gastrointestinal Permeation Enhancement Technology (GIPET), Eligen, Peptelligence, Oral antibody platform, Multi-Matrix Systems (MMX) and others. GIPET, Eligen and Peptelligence are some of the prominent technologies used in oral protein and peptides formulations development.

Oral Proteins and Peptides Market analysis by Geography

Geographically, the market is segmented into North America, Europe, Asia-Pacific and the LAMEA. North America is the most eminent market of oral proteins and peptides market.

Competitive Landscape

Zydus cadilla Healthcare, Pfizer, Inc., Roche, Inc., Sanofi-Aventis LLC, Abbott Laboratories, Novartis AG are the major key players of this market. Many large and small companies are doing in-house research for developing new technologies. Several proteins and peptides are in preclinical and discovery stage.

High level analysis

According to Porter's five forces model, the bargaining power of buyers is high due to limited number of sellers in the market and bargaining power of buyers is less, as there is no substitute available in the market. Threat of new entrant is less due to high capital investment require for start- up. SWOT analysis gives direction for strategic planning. Major Key players are focusing on Research and Development. Many products are of key players are under preclinical trials and clinical trials.

KEY BENEFITS

-Understanding of drivers and restraints helps to develop business strategies according to the business environment
-Market entry and market expansion strategies can be planned on the basis of segmentation of market
-Analysis of strategies adopted by key players helps to strengthen market position
-Long term profit and growth strategies can be tailored through porter's five forces model and SWOT analysis

KEY DELIVERABLES

Oral proteins and peptide market is segmented on the basis of drugs available, technology used for development and geography.

MARKET BY DRUGS

-Linaclotide
-Ostora
-IN-105(Insulin)
-Plecantide
-Others

MARKET BY TECHNOLOGY

-Gastrointestinal Permeation Enhancement Technology (GIPET)
-Eligen
-Peptelligence
-Oral antibody platform
-Multi-Matrix Systems (MMX)
-Others

MARKET BY GEOGRAPHY

-North America
-Europe
-Asia-Pacific
-LAMEA